Alexander Alexandov, MD: Founder and Chief Executive Officer / Chief Medical Officer

Dr. Alexandrov has over 20 years of experience in biotech and pharmaceutical business. Prior MYR Pharma, Alexander held executive positions in the German companies Vision7and Fresenius Biotech, where he was responsible for the development of key clinical products. He started his career as a researcher at University Clinic Essen in Germany. Alexander co-founded MYR Pharma in 2011 and has been the key driver of Myrcludex B development from preclinical studies through the advanced clinical stage.  Alexander holds the degrees of Doctor of Medicine from the University of Essen, Germany and Medical Doctor from Nizhny Novgorod Medical Academy, Russia.


Jörn Möller, PhD: Chief Financial Officer

Dr. Möller is a Founder and current CFO of MYR Pharma. His background is in economics. Dr. Möller previously served as Chief Financial Officer of the German departments store chain Kaufhof, and of the Continental Group companies. Over the last two decades, he has been active as a business angel and CFO of biotechnology companies.

Alexey Eliseev, PhD, MBA:  Chief Business Officer

Alexey’s career includes 25 years of experience in academia, biotechnology industry and venture capital. Following an academic career as a Professor of Medicinal Chemistry at SUNY Buffalo, he was a co-founder of a number of successful biotechnology companies, including Alantos Pharmaceuticals (Germany/USA), AC Immune (Switzerland) and MirImmune (USA). Alexey worked with the Maxwell Biotech Venture Fund as its Managing Director and Venture Partner since 2009 and oversaw the fund’s investment in MYR Pharma. Prior to joining MYR as an executive, Alexey served as Chief Business Officer of RXi Pharmaceuticals (USA). Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the Massachusetts Institute of Technology.